DIRS.INFO The most relevant business & tech news

☆ Abbott Labs' surprise guidance bump is a major positive for its shareholders
▼ + stars: | 2024-04-17 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Abbott Laboratories Why we own it : Abbott is a high-quality medtech company growing at a fast clip. As Abbott's organic sales growth continues to shine, the market will realize both concerns are overblown. We also love that EPS results on Tuesday came in above the range management had forecasted — a classic case of under-promising and over-delivering. ABT YTD mountain Abbott Laboratories YTD Organic growth was very strong, up nearly 11%, marking the fifth consecutive quarter of double-digit increases. In diagnostics, where we see the impact of the decline in Covid testing sales, organic sales increased 5.4% year over year.

Persons: —, Abbott, Edwards, Robert Ford, necrotizing, Ford, they've, Jim Cramer's, ABT, Jim Cramer, Jim Organizations: Abbott Laboratories, Revenue, Abbott, Libre, Charitable Trust, ABT, Management, NEC, Protality, TBIs, CNBC, Abbott Labs Locations: U.S

☆ Labour opposition deals another historic blow to UK PM Rishi Sunak with by-election defeats
▼ + stars: | 2024-02-16 | by ( Elliot Smith | ) www.cnbc.com time to read: +4 min

Winning candidate Gen Kitchen said the result was a "stunning victory for the Labour Party and must send a message from Northamptonshire to Downing Street." LONDON — U.K. Prime Minister Rishi Sunak's ruling Conservative Party suffered another double by-election defeat on Thursday, as the opposition Labour Party's momentum shows no sign of slowing. The double defeat of Thursday was the latest in a string of unfavorable by-election results for the ruling party in what were previously considered safe seats. "I was very pleased last night to see that we were clearly getting Tory switchers, in other words people who hadn't voted for the Labour Party before, coming out last night and voting for the Labour Party in a by-election." The Labour Party maintains a lead of more than 20 points over the Conservatives in all national polling, with a general election due no later than January 2025.

Persons: Kitchen, Peter Bone, —, Rishi Sunak's, Helen Harrison, Gen Kitchen, Chris Skidmore, Damien Egan, Keir Starmer, Tory switchers, hadn't, Boris Johnson, Robert Ford Organizations: Labour, Labour Party, Downing, Conservative, Conservatives, LONDON, Conservative Party, Kettering Leisure Village, Tamworth, Liberal Democrats, BBC, University of Manchester, CNBC Locations: Northamptonshire, Wellingborough , Northamptonshire, KETTERING, England, Wellingborough, Kettering, Kettering , England, Kingswood , South Gloucestershire, North, Kingswood, Mid Bedfordshire, West Midlands, Selby, Ainsty, Somerton, Frome

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

— Lisa Kailai Han 7:07 a.m. — Lisa Kailai Han 6:48 a.m. "At current levels, we believe the risk/reward skews to the downside," wrote analyst Paul Lejuez. — Lisa Kailai Han 6:05 a.m. — Lisa Kailai Han

Persons: Robert Ford Aguilar, Aguilar, Lisa Kailai Han, Rachel Vatnsdal, GeoMx, Vatnsdal, skews, Paul Lejuez, — Lisa Kailai Han, Nik Modi, Raymond James, Matt Roberts, headwinds, Roberts, Ashwani Verma, Verma, Morgan Stanley, Micron Morgan Stanley, Joseph Moore's, Moore, Amit Mehrotra, Mehrotra, Sangita Jain, Jain, Fred Imbert Organizations: CNBC, Monday, UBS, Teva Pharmaceutical, Bloom Energy, Bank of America, Arcos Dorados Bank of America, Arcos Dorados, ARCO, JPMorgan downgrades, JPMorgan, U.S, District, Prognosys, 10X Genomics, Citi, RBC, RBC Capital Markets, UBS downgrades Jazz Pharmaceuticals, Jazz Pharmaceuticals, Digital, Micron, Western, Deutsche Bank, BE Locations: America, Caribbean, Argentine, Delaware, NSTG, U.S, Europe, Mondelez, narcolepsy

☆ Corporate America weighs business impact of new weight-loss drugs
▼ + stars: | 2023-11-08 | by ( ) www.reuters.com time to read: +4 min

Walmart (WMT.N) expects revenues from its health and wellness products to increase in the second half of the year, mainly due to the popularity of weight-loss drugs. PepsiCo (PEP.O) Chief Financial Officer Hugh Johnston has said the company is "not seeing any impact" yet from the popularity of weight-loss drugs. Coca-Cola (KO.N) CEO James Quincey said the company was monitoring what impact, if any weight-loss drugs will have. Abbott CEO Robert Ford has said diabetes patients could end up using glucose monitors with the weight-loss drugs in the long term. DRUG DISTRIBUTORSCencora (COR.N), formerly called AmerisourceBergen, Cardinal Health (CAH.N) and McKesson (MCK.N) have flagged potential boost to revenues this year owing to the growing demand for weight-loss drugs.

Persons: Victoria Klesty, Eli Lilly's, Eli Lilly's Zepbound, Hugh Johnston, James Quincey, Michele Buck, Dr Pepper, Robert Gamgort, Johnson, Joseph Wolk, Robert Ford, Michael Farrell, Bhanvi Satija, Ananya Mariam Rajesh, Mrigank Dhaniwala, Arun Koyyur Organizations: REUTERS, U.S . Food, Drug Administration, Walmart, PepsiCo, J, Abbott Laboratories, Insulet Corp, Boston Scientific, Cardinal Health, Thomson Locations: Oslo, Norway, Victoria, U.S, GLP, Bengaluru

☆ Corporate America weighs risks of the Ozempic effect
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +3 min

Walmart (WMT.N) expects revenues from its health and wellness products to increase in the second half of the year, mainly due to the popularity of weight-loss drugs. PepsiCo (PEP.O) Chief Financial Officer Hugh Johnston has said the company is "not seeing any impact" yet from the popularity of weight-loss drugs. Abbott Laboratories (ABT.N), which makes glucose monitoring products, has said that the market was overestimating the impact to its sales from growing popularity of the drugs. Abbott CEO Robert Ford has said that diabetes patients could end up using glucose monitors with the weight-loss drugs in the long term. DRUG DISTRIBUTORSCencora (COR.N), formerly called AmerisourceBergen, Cardinal Health (CAH.N) and McKesson (MCK.N) have flagged potential boost to revenues this year owing to the growing demand for weight-loss drugs.

Persons: George Frey, Eli Lilly's, Hugh Johnston, Johnson, Joseph Wolk, Robert Ford, Bhanvi, Mrigank Organizations: Novo Nordisk, Pharmacy, REUTERS, Walmart, PepsiCo, Abbott Laboratories, Insulet Corp, Cardinal Health, Thomson Locations: Provo , Utah, U.S, Bengaluru

REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsOct 18 (Reuters) - Abbott Laboratories (ABT.N) said the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs, adding the treatments could end up boosting sales of the medical device maker. The company's shares have dropped 16% this year, mainly on concerns that new GLP-1 diabetes drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro could eat into the sales of its continuous glucose monitoring (CGM) devices. Hurdles in health insurance reimbursement and pricing could, however, keep market growth for GLP-1 drugs limited to a small number of patients in the near term, Abbott CEO Robert Ford said on Wednesday. Third-quarter sales of FreeStyle Libre, Abbott's CGM device used by diabetes patients, jumped 30.5% to $1.4 billion, lifting Abbott's shares 3% in morning trade. The numbers helped Abbott's medical device sales that stood at $4.25 billion, beating analysts' estimates of $4.16 billion, according to LSEG data.

Persons: Brendan McDermid, Nordisk's Ozempic, Eli Lilly's, Abbott, Robert Ford, Ford, Vijay Kumar, Pratik Jain, Leroy Leo, Anil D'Silva, Shounak Dasgupta, Shinjini Organizations: Abbott, New York Stock Exchange, REUTERS, Abbott Laboratories, Nordisk's, Thomson Locations: New York City, U.S, GLP, Bengaluru

☆ 'We don't see' weight-loss drugs impacting medical devices' sales, says Abbott CEO Robert Ford
▼ + stars: | 2023-10-18 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email'We don't see' weight-loss drugs impacting medical devices' sales, says Abbott CEO Robert FordRobert Ford, Abbott chairman and CEO, joins 'Closing Bell Overtime' to talk Q3 earnings, the impact of weight loss drugs on their product and more.

Persons: Robert Ford Robert Ford, Abbott

☆ As Covid-testing business drops, Abbott searches for new line of business with consumer wearables
▼ + stars: | 2023-10-10 | by ( Ashley Capoot | ) www.cnbc.com time to read: +3 min

Abbott Laboratories CEO Robert Ford took the stage at the HLTH conference in Las Vegas on Tuesday to discuss the company's expansion into a new market: consumer wearables. For instance, Abbott produces a continuous glucose monitor (CGM) called FreeStyle Libre that patients can use to manage their diabetes. Abbott's most recent model, the FreeStyle Libre 3, can measure glucose levels in real time for up to 14 days. FreeStyle Libre alone generated more than $1.3 billion in sales for Abbott during its second quarter, according to the company's earnings report. "We always believed that we could take this platform that we developed for diabetes and expand it beyond diabetes," Ford said.

Persons: Robert B, Ford, Robert Ford, Abbott, Covid, Margaret Kaczor Andrew, William Blair, CNBC's Erin Black, Lingo Organizations: Abbott, Libre, wearables Locations: Vegas, Las Vegas , Nevada, Las Vegas, U.S

Abbott CEO Robert Ford said the great momentum in device and diagnostics sales during the quarter was due to improving market conditions in healthcare. Rival J&J's (JNJ.N) medical device segment also topped estimates, aided by a recovery in demand for medical procedures. Shares of rival medical device makers Medtronic (MDT.N) and Boston Scientific Corp (BSX.N) rose nearly 3%. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from diabetes device Freestyle Libre, beating analysts' estimates of $4.10 billion. Abbott's adjusted profit of $1.08 per share in the quarter beat analysts' estimates of $1.05.

Persons: Robert Ford, J, Shagun Singh, Abbott, Khushi Mandowara, Pooja Desai Organizations: Abbott Laboratories, RBC Capital Markets, Boston Scientific Corp, U.S, Thomson Locations: Michigan, Bengaluru

Abbott is the second major company to signal a recovery in medical device sales. Medical devices - Abbott's largest segment - clocked an 8.5% rise in sales to $3.90 billion, with $1.2 billion coming from glucose monitoring device Freestyle Libre. I don't think it's a bolus of backlog," Abbott CEO Robert Ford said about the recovery in medical device sales. The stronger outlook for its non-COVID business was the main takeaway as investors had priced in a fall in COVID testing sales, J.P. Morgan analyst Robbie Marcus said in a note. Abbott lowered its outlook for COVID testing sales this year to $1.5 billion from the $2 billion it forecast in January.

☆ Abbott Labs shares pop as revenue, earnings defy steep drop in Covid test sales
▼ + stars: | 2023-04-19 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Abbott Laboratories popped Wednesday after the company's earnings and revenue topped Wall Street's expectations, defying a dramatic slowdown in sales of its Covid-19 tests. Abbott reported revenue of $9.7 billion for the first quarter, slightly surpassing the Refinitiv estimate of $9.64 billion due to recovery in its medical devices business. Strong sales in Abbott's medical devices business fueled the company's first-quarter beats. The unit raked in $3.9 billion in sales during the quarter, up nearly 9% from the same period last year. That comes after rival Johnson & Johnson reported strong growth in its own medical devices unit, noting that surgical procedures are "well in recovery."

But that higher inflation has already been baked into many tax and wage figures that will change in 2023. Income tax bracketsThe IRS tax brackets corresponding to your marginal tax rates are also shifting upward — by 7% — thanks to inflation. But many banks, especially those that are online-only, are also paying out more money through higher interest rates for high-yield savings and certificate of deposit accounts. California is the largest state that will see a cost of living adjustment next year, with the minimum wage rising to $15.50 for all establishments. California's increase is limited by a statute that declares the minimum wage cannot increase by more than 3.5% each year.

☆ Abbott Names New Leadership at Troubled Baby-Formula Plant
▼ + stars: | 2022-10-19 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Abbott Laboratories has made leadership changes at its major baby-formula manufacturing plant and in its quality organization, following a temporary shutdown of the Sturgis, Mich., plant earlier this year after contamination was found. The Abbott Park, Ill., company also plans to spend about $500 million to build a new baby-formula plant in the U.S., after analyzing the market and concluding more capacity is needed, Chief Executive Robert Ford said Wednesday.

☆ Abbott plans new $500 million infant formula facility as shortage continues
▼ + stars: | 2022-10-19 | by ( Katherine Dillinger | ) edition.cnn.com time to read: +3 min

CNN —Abbott Nutrition plans to build a $500 million nutrition facility for specialty and metabolic infant formulas, Chairman and CEO Robert Ford said Wednesday. The announcement comes as the US formula shortage continues and experts have called for more domestic production and diversity among suppliers. “We’re currently in the final stages of determining the site location and will work with regulators and other experts to ensure this facility is state-of-the-art and sets a new standard for infant formula production. More than 40% said they had only a week’s supply or less on hand. “We also boosted production in our global network to increase infant formula supply to the US.

☆ The Columbus, Ohio, Warehouse Boom: How warehouses brought stifling dust and diesel fumes — and a chance for refugees to grab the American dream
▼ + stars: | 2022-10-19 | by ( Emma Cosgrove | Katherine Long | ) www.businessinsider.com time to read: +27 min

What binds them, despite different nationalities, immigration stories, and languages, are warehouse jobs. As Columbus' warehouse development begins encroaching into residential areas, a consensus is gathering here — as it has elsewhere — that warehouses make for poor neighbors. Tariq Tarey for InsiderIn Canal Winchester, Halstead's efforts to put the question of warehouse development before voters were stymied. The town council bypassed her group's referendum by declaring a state of emergency to approve the warehouse development. There aren't clear lines between the winners and losers of Columbus' warehouse boom.

☆ ‘Blonde’ Review: More Marilyn Mythologizing
▼ + stars: | 2022-09-28 | by ( John Anderson | ) www.wsj.com time to read: +1 min

The public’s endless fascination with Marilyn Monroe might not be exhausted, finally, by “Blonde,” but the viewer will be. At two hours and 47 minutes, Andrew Dominik ’s pseudo-biography is one long slog into sadness and more-than-predictable tragedy, despite a touching portrayal by Ana de Armas and the deliberately artful and often startling filmmaking of Mr. Dominik. If you’re wondering if men are swine, they are, at least according to his adaptation of the Joyce Carol Oates novel. In some ways, Monroe was the human exemplar of the observer effect in physics: When we look at a thing, the thing changes. No one in the history of Hollywood has been looked at more intensely than Monroe.

☆ Ana de Armas’ fearless performance deserves a better movie than ‘Blonde’
▼ + stars: | 2022-09-28 | by ( Review Brian Lowry | ) edition.cnn.com time to read: +4 min

It’s not a fresh take or a wrong one, but the tone is so self-conscious and surreal as to blunt those insights. Dominik also distastefully deals with Monroe’s lost pregnancies by peeking at the fetus inside her, which becomes symbolic of just how overdone much of the movie is. Still, “Blonde” is almost wholly de Armas’ show, and to the extent it’s worth sitting through at all give her every ounce of credit. Indeed, once you get past admiring de Armas’ immersion into the role, that’s the only itch that “Blonde” seems to know how to scratch. “Blonde” premieres September 16 in select US theaters and September 28 on Netflix.

☆ 'Blonde' review: Ana de Armas stars as Marilyn Monroe in a pretentious, overlong, NC-17 Netflix movie
▼ + stars: | 2022-09-15 | by ( Review Brian Lowry | ) edition.cnn.com time to read: +4 min

Netflix will surely get its money’s worth attention-wise thanks in part to its restrictive NC-17 rating, but the film’s merits burn out long before its credits ever roll. It’s not a fresh take or a wrong one, but the tone is so self-conscious and surreal as to blunt those insights. Norma Jeane is eventually transformed into Marilyn Monroe, but even then she consistently speaks of her star persona in the third person, as if the image stands apart and utterly separate from the human being behind it. Still, “Blonde” is almost wholly de Armas’ show, and to the extent it’s worth sitting through at all give her every ounce of credit. Indeed, once you get past admiring de Armas’ immersion into the role, that’s the only itch that “Blonde” seems to know how to scratch.

☆ Calitatea educației la Școala Internațională Heritage, recunoscută mondial printr-un nou titlu, în premieră pentru Moldova
▼ + stars: | 2021-07-02 | by ( Onixmedia Srl | ) diez.md time to read: +4 min

Din cauza pandemiei, etapa finală a evaluării a fost efectuată online, în ultima săptămână a lunii mai. Aceasta este o onoare și o realizare importantă pentru întreaga Comunitate Heritage. COBIS a subliniat că Școala Internațională Heritage a demonstrat că este, chiar de la deschidere, o școală vizionară și ambițioasă în Moldova și în regiune. COBIS a apreciat, de asemenea, angajamentul extins al școlii față de comunitatea națională și implicarea pentru dezvoltarea educației. Robert Ford, directorul Școlii Internaționale Heritage: „Suntem foarte mândri de ce am realizat la finalul acestui an școlar extraordinar.

Persons: COBIS, Echipa COBIS, Heritage, Natalia Cecetova, Sinan Bora, Robert Ford Organizations: Internaționale Britanice, Echipa, Internațională Heritage, Heritage Locations: Londra, Moldova, Europa, Asia, Africa, Orientul Mijlociu, America

☆ Tată pe messenger. Cum să păstrezi relația cu copiii la distanță — Moldova.org
▼ + stars: | 2020-12-12 | by ( Diana Preașcă | ) www.moldova.org time to read: +11 min

Echipa continuă să lucreze pentru dezvoltarea școlii și a elevilor săi – viitorii lideri ai acestei lumi. Arată foarte bine, deoarece cred că am echipa cea mai experimentată în învățarea la distanță, capabilă să facă față crizelor și foarte centrată pe elev! Elevii noștri nu vor trece prin sistemul național de bacalaureat, ei vor susține examenele „A Level” și vor obține calificările Cambridge recunoscute la nivel global. Suntem un centru de dezvoltare profesională Cambridge și pilotăm inițiativele Cambridge. Trăim vremuri schimbătoare, dar și Școala Internațională Heritage se schimbă, odată cu introducerea programului „A Level”, de exemplu.

Persons: Robert Ford, Crăciun, Margaret Thatcher . Ea, coronavirusului, Harris, Maia Sandu Organizations: Internațională Heritage, Heritage, Internaționale Heritage, UNICEF, Cambridge International, Universitatea Oxford, Facebook Locations: Moldova, Cambridge, Honduras, Irlandei, Somerville, Europa, Oxford, străinătate

☆ Robert Ford, directorul Școlii Internaționale Heritage, despre noul liceu cu program Cambridge: „Nu a mai existat așa ceva în Moldova, suntem mândri să fim primii”
▼ + stars: | 2020-12-11 | by ( Onixmedia Srl | ) diez.md time to read: +11 min

Echipa continuă să lucreze pentru dezvoltarea școlii și a elevilor săi – viitorii lideri ai acestei lumi. Vorbim despre inovațiile și perspectivele pentru 2021 cu Robert Ford, directorul Școlii Internaționale Heritage. — Arată foarte bine, deoarece cred că am echipa cea mai experimentată în învățarea la distanță, capabilă să facă față crizelor și foarte centrată pe elev! Elevii noștri nu vor trece prin sistemul național de bacalaureat, ei vor susține examenele „A Level” și vor obține calificările Cambridge recunoscute la nivel global. Suntem un centru de dezvoltare profesională Cambridge și pilotăm inițiativele Cambridge.

☆ 2020-12-11 — Moldova.org
▼ + stars: | 2020-12-11 | by ( ) www.moldova.org time to read: 1 min

Robert Ford, directorul Școlii Internaționale Heritage, despre noul liceu cu program Cambridge: „Nu a mai existat așa ceva în Moldova, suntem mândri să fim primii”Al patrulea an pentru Școala Internațională Heritage din Moldova s-a dovedit a fi unul provocator, dar și plin de oportunități. Una dintre aceste oportunități este reprezentată...

Persons: Robert Ford Organizations: Internaționale, Internațională Heritage Locations: Cambridge, Moldova

☆ O inventatoare de 15 ani a fost declarată copilul anului, potrivit revistei TIME — Moldova.org
▼ + stars: | 2020-12-07 | by ( Eugenia Wetz | ) www.moldova.org time to read: +11 min

Echipa continuă să lucreze pentru dezvoltarea școlii și a elevilor săi – viitorii lideri ai acestei lumi. Arată foarte bine, deoarece cred că am echipa cea mai experimentată în învățarea la distanță, capabilă să facă față crizelor și foarte centrată pe elev! Elevii noștri nu vor trece prin sistemul național de bacalaureat, ei vor susține examenele „A Level” și vor obține calificările Cambridge recunoscute la nivel global. Suntem un centru de dezvoltare profesională Cambridge și pilotăm inițiativele Cambridge. În calitate de director, sunt foarte implicat în acest proces, datorită experienței mele de a conduce un liceu imens cu 400 de elevi „A Level”.

Search resuls for: "Robert Ford"

24 mentions found